Research programme: raf kinase inhibitor - Takeda
Alternative Names: pan-Raf inhibitor - Takeda; TAK-632Latest Information Update: 04 Nov 2017
Price :
$50 *
At a glance
- Originator Takeda
- Class Amides; Benzothiazoles; Fluorobenzenes; Nitriles; Small molecules
- Mechanism of Action Raf kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer; Malignant melanoma
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in Japan
- 16 Jul 2016 No recent reports of development identified for preclinical development in Malignant-melanoma in Japan
- 22 Oct 2013 Preclinical trials in Cancer in Japan (unspecified route)